1. Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective

2. GLP-1: Effects in Humans

3. FDA-Approved GLP-1 RAs

4. GLP-1 RAs and HbA1c Head-to-Head Trials

5. Tolerability of GLP-1 RAs

6. GLP-1 RAs in Development

7. ITCA 650 Exenatide

8. ITCA 650 Continuous Delivery of Exenatide

9. SUSTAIN-1 Once-Weekly Semaglutide Monotherapy

10. Patients Achieving < 7.0% and ≤ 6.5% HbA1c Target at Week 30

11. Patients Achieving HbA1c < 7
Patients Achieving HbA1c < 7.0% Without Severe Hypoglycemia and No Weight Gain at Week 30

12. ITCA 650: FREEDOM-1 Trial

13. CVOTs for GLP-1 RAs

14. Medication Adherence Scope of the Problem

15. Only About One-Third of Patients Are Adherent to GLP-1 RAs

16. Patient Challenges With GLP-1 RAs and Success of Treatment

17. Where Will These Emerging GLP-1 RAs Fit Into Clinical Practice in the Future?

18. Concluding Remarks